ICON Executive and Leadership Team

Connie Inguanti, the President, Symphony Health at ICON, directs the integration of advanced data analytics into the drug development lifecycle. Overseeing the Symphony Health division, Inguanti architects data-driven solutions that empower pharmaceutical clients to optimize commercialization strategies. This leadership role involves managing complex datasets to identify market trends and patient outcomes across North American and European markets. By leveraging proprietary health information, Connie Inguanti ensures that ICON provides actionable insights for medical device and biotechnology partners. The President, Symphony Health maintains rigorous standards for data integrity while driving innovation in real-world evidence generation. Through strategic oversight of analytical platforms, Inguanti supports the broader corporate mission of accelerating clinical research. This focus on data precision directly enhances the efficiency of drug development programs, ultimately securing better health outcomes for patients globally.

Deepali Suri, the President, ICON Biotech at ICON, manages the specialized development services tailored for emerging biotechnology firms. Overseeing the ICON Biotech unit, Suri drives the execution of clinical trials and regulatory pathways for innovative medical products. This leadership role requires close collaboration with the Board to align biotech-specific service offerings with the evolving needs of the global pharmaceutical industry. By streamlining development timelines, Deepali Suri ensures that clients navigate complex regulatory landscapes with agility and precision. The President, ICON Biotech focuses on scaling operational capacity to support high-growth biotech ventures across international markets. Through the implementation of advanced clinical methodologies, Suri enhances the competitive positioning of the company within the R&D sector. This strategic direction fosters long-term partnerships with biotechnology innovators, ensuring that the organization remains at the forefront of medical advancement and commercial success.

Thomas Marsland, the President at ICON, directs the overarching corporate strategy and operational excellence across all global business units. Overseeing the execution of high-level organizational goals, Marsland ensures that the company maintains its market leadership in drug and device development services. This leadership role involves coordinating with other C-suite executives to optimize resource allocation and drive sustainable revenue growth. By fostering a culture of innovation, Thomas Marsland supports the delivery of comprehensive commercialization services to government and public health organizations. The President monitors global market shifts to adjust service delivery models, ensuring that the organization remains responsive to the needs of the pharmaceutical and medical device sectors. Through disciplined management of corporate initiatives, Marsland strengthens the operational foundation of the company. This strategic focus on efficiency and growth directly impacts the ability of the firm to provide high-quality research and development support on a global scale.

Marian Colon-Nieves, the Manager, Clinical Operations & Chief People Officer at ICON, directs the intersection of human capital management and clinical trial execution. Overseeing the talent acquisition and development strategies, Colon-Nieves ensures that the organization retains the specialized expertise required for complex drug development projects. This leadership role involves aligning workforce capabilities with the operational demands of clinical research teams across diverse geographic regions. By optimizing internal processes, Marian Colon-Nieves drives efficiency in clinical operations while simultaneously fostering a high-performance culture. The Manager, Clinical Operations & Chief People Officer collaborates with executive leadership to implement organizational structures that support rapid scaling and service delivery. Through the integration of people-centric policies and operational rigor, Colon-Nieves enhances the overall productivity of the company. This dual focus on human resources and clinical excellence ensures that the firm maintains a competitive edge in the global biotechnology and pharmaceutical services market.